study_id,year,design,effect_type,effect_point,ci_low,ci_high,n_treat,n_ctrl,risk_of_bias,doi,journal_id,outcome,population,adverse_events,duration_weeks
INFL-INF02-01,2020,randomized controlled trial,SMD,-0.2804,-0.4138,-0.147,82,95,low,10.1234/infl-inf02-01,inflammation-journal-01,systemic_inflammation,Adults with systemic inflammation concerns,None reported,10
INFL-INF02-02,2011,randomized controlled trial,SMD,-0.275,-0.4608,-0.0892,95,80,low,10.1234/infl-inf02-02,inflammation-journal-02,systemic_inflammation,Adults with systemic inflammation concerns,None reported,8
INFL-INF02-03,2016,randomized controlled trial,SMD,-0.2696,-0.4378,-0.1014,78,94,some concerns,10.1234/infl-inf02-03,inflammation-journal-03,systemic_inflammation,Adults with systemic inflammation concerns,Transient headache,13
